SCHEMBL615787

SCHEMBL615787

CCOC(=O)C(=[N+]=[N-])C(=O)c1cccnc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.44
CYP1A2 P05177 2/20 0.41
MAPT P10636 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPK1 P28482 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.39
LMNA P02545 3/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
ALDH1A1 P00352 3/20 0.37
TSHR P16473 1/20 0.36
KMT2A Q03164 3/20 0.36
ATM Q13315 1/20 0.36
MEN1 O00255 2/20 0.36
CYP2C9 P11712 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831449 0.85 NAPRT (0.53) NAPRTCYP1A2MAPTCYP2C19CYP3A4
SCHEMBL4770453 0.85 CYP2C19 (0.46) CYP1A2MAPTCYP2C19CYP3A4CYP2D6
SCHEMBL3787061 0.81 CES2 (0.47) CYP1A2MAPTCYP2C19CYP3A4LMNA
SCHEMBL6297502 0.81 CYP2C19 (0.43) CYP1A2MAPTCYP2C19CYP3A4CYP2D6
SCHEMBL21963668 0.79 MAPT (0.39) CYP1A2MAPTCYP2C19CYP3A4CYP2D6
SCHEMBL13310387 0.77 CES2 (0.49) NAPRTCYP1A2MAPTCYP2C19CYP3A4
SCHEMBL3709449 0.77 CYP11B1 (0.43) CYP1A2MAPTCYP2C19LMNAPOLB
SCHEMBL12897074 0.76 TSHR (0.59) NAPRTMAPTMAPK1LMNANPC1
SCHEMBL884798 0.76 CES2 (0.47) MAPTLMNAALDH1A1TSHRKMT2A
SCHEMBL14875422 0.74 CES2 (0.46) CYP1A2MAPTCYP2C19LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421366-B1 HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2013-08-28 EP disclosed
US-8293744-B2 Heterocyclic fused cinnoline M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2012-10-23 US disclosed
EP-2421366-A1 HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck Sharp & Dohme Corp. (US) 2012-02-29 EP disclosed
US-20120040978-A1 Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME CORP. (US) 2012-02-16 US disclosed
WO-2010123716-A1 HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040978-A1 Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators CHRM1, CNR1, CHRNA7 NAPRT 1831/4885CYP1A2 557/4885MAPT 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.